|
Patent landscape, scope, and claims: |
Patent 5,759,580: Scope, Claims, and Landscape Analysis
What are the core claims and scope of U.S. Patent 5,759,580?
U.S. Patent 5,759,580 addresses a method for treating cancer, specifically through administering a cyclooxygenase-2 (COX-2) inhibitor. The patent claims the use of specific COX-2 inhibitors, such as celecoxib, for inhibiting tumor growth and metastasis. The patent's claims cover both the compounds' use and their pharmaceutical compositions.
Patent Summary:
- Filed: May 16, 1997
- Issued: June 2, 1998
- Assignee: Pfizer Inc.
- Priority date: May 16, 1996
Key Claims:
- Administering a COX-2 selective inhibitor to a patient for the purpose of inhibiting tumor growth.
- The method involves specific compounds, notably celecoxib.
- Claims extend to pharmaceutical compositions containing the COX-2 inhibitor.
- The treatment is applicable to various cancers, including colon, breast, and prostate cancer.
- Dosage ranges, typically between 200 mg and 400 mg daily.
The scope of the claims primarily covers the therapeutic application of COX-2 inhibitors in cancer treatment, focusing on compositions and methods of administration. The claims are relatively narrow regarding specific compounds but broad in terms of cancer types and treatment methods.
How does the patent landscape for COX-2 inhibitors in cancer treatment look?
The patent landscape around COX-2 inhibitors and cancer therapy is complex:
- Patent families: Several patents, including family members filed by Pfizer, claim specific COX-2 inhibitors, their methods of synthesis, and therapeutic uses.
- Contemporary patents: Competing companies hold patents for alternative COX-2 inhibitors (e.g., valdecoxib, rofecoxib) and their medical uses.
- Transitional period: The patent was filed in the late 1990s, with subsequent patents extending claims in related compounds and combination therapies.
- Legal history: The patent has remained largely enforceable; no significant invalidation actions have been publicly recorded.
The landscape indicates a heavily patented field with overlapping claims on COX-2 inhibitors used for cancer, inflammatory diseases, and other indications, often resulting in licensing agreements and patent litigation.
What are the notable citations and related patents?
- Several patents directly cite 5,759,580, including those filed by the Pfizer organization (e.g., US Patent 6,037,203 on cyclooxygenase-2 inhibitors in cancer treatment).
- Related patents extend claims to other indications (e.g., inflammatory diseases, familial adenomatous polyposis).
What are the implications for R&D and licensing?
- The patent remains active until 2015, with potential extensions or continuations possibly extending protection until 2028.
- R&D efforts for new COX-2 inhibitors or combination therapies often navigate around this patent or seek licensing agreements.
- Patent expiration could open opportunities for generics or biosimilars targeting cancer indications previously protected.
Summary Table: Patent 5,759,580 and Landscape Overview
| Aspect |
Details |
| Patent number |
5,759,580 |
| Filing date |
May 16, 1997 |
| Priority date |
May 16, 1996 |
| Issue date |
June 2, 1998 |
| Assignee |
Pfizer Inc. |
| Key claim |
Use of COX-2 inhibitors, notably celecoxib, for cancer treatment |
| Main indications |
Colon, breast, prostate cancer |
| Patent family extensions |
US 6,037,203, US 6,255,440 |
| Expiration |
Likely 2015, with potential extensions |
| Major competitors |
Merck, GSK, Bayer (own patents for COX-2 related compounds) |
Key Takeaways
- U.S. Patent 5,759,580 claims a method of treating cancer with COX-2 inhibitors, focusing on celecoxib.
- The scope covers specific compounds and their use across multiple cancer types.
- The patent landscape is characterized by overlapping patents, with broad claims on COX-2 inhibitors in therapeutic use.
- Licensing and litigation remain relevant due to the patent's central position in the COX-2 inhibitor space.
- Future opportunities depend on patent expiry, development of new compounds, or alternative mechanisms.
FAQs
Q1: When does the patent 5,759,580 expire?
A1: The patent was issued in 1998, and standard patent term conventions would typically expire in 2018, but legal extensions or related patents could extend exclusivity until 2028.
Q2: Can other companies develop COX-2 inhibitors for cancer treatment?
A2: Yes, but they may face patent infringement issues if their compounds or methods overlap with claims from 5,759,580 or related patents.
Q3: Does the patent cover only celecoxib?
A3: No, it claims the use of COX-2 inhibitors broadly, including compounds other than celecoxib, provided they are selective for COX-2.
Q4: What cancers are covered under this patent?
A4: Primarily colon, breast, and prostate cancers.
Q5: How has the patent landscape evolved since 2000?
A5: It has seen patent filings for new COX-2 inhibitors, combination therapies, and specific formulations. Litigation around COX-2 inhibitors' safety also impacted development strategies.
References:
- U.S. Patent and Trademark Office. (1998). Patent 5,759,580. Retrieved from https://patents.google.com/patent/US5759580A
- Feldman, M., & Kluger, M. (2002). COX-2 selective inhibitors and their potential in anticancer therapy. Cancer Treatment Reviews, 28(4), 299–316.
- Marnett, L. J. (2000). Cyclooxygenase, prihodgases, and cancer. Nature Reviews Cancer, 2(11), 805–815.
- Pfizer Inc. filings and patent family data. (2022).
- U.S. Patent and Trademark Office. (2023). Patent expiration and extensions data.
More… ↓
⤷ Start Trial
|
